Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

authID® Completes New Financing Round and Announces New 10-03-2023, 05:48

YY Group Holding Limited Secures US$5 Million in New Facility Services Contracts 5-08-2025, 19:30